首页/数据集/Table S1 - A Descriptive Model of Patient Readiness, Motivators, and Hepatitis C Treatment Uptake among Australian Prisoners

Table S1 - A Descriptive Model of Patient Readiness, Motivators, and Hepatitis C Treatment Uptake among Australian Prisoners

NIAID Data Ecosystem2026-03-08 收录

丙型肝炎治疗

囚犯健康行为

数据链接：

https://figshare.com/articles/dataset/_A_Descriptive_Model_of_Patient_Readiness_Motivators_and_Hepatitis_C_Treatment_Uptake_among_Australian_Prisoners_/946410 数据链接链接失效反馈

官方服务：

资源简介：

HePATO Qualitative Research Interview Question Guidelines. (DOCX)

应用场景：

创建时间：

2014-02-27

丙型肝炎治疗

T细胞免疫重建

We analyzed hepatitis C virus (HCV)-specific T cells and non-specific memory T cell populations from 6 patients with chronic HCV infection receiving 12 weeks of direct-acting antiviral (DAA) therapy w

NIAID Data Ecosystem80

丙型肝炎治疗

直接抗病毒药物荟萃分析

This data archive contains the following 7 files relating to treatment optimisation for hepatitis C in the era of combination direct-acting antiviral therapy: - Supplementary figure 1: Thematic map

NIAID Data Ecosystem50

Modelling how responsiveness to interferon improves interferon-free treatment of hepatitis C virus infection

丙型肝炎治疗

多尺度病毒动力学模型

Direct-acting antiviral agents (DAAs) for hepatitis C treatment tend to fare better in individuals who are also likely to respond well to interferon-alpha (IFN), a surprising correlation given that DA

Figshare2018-07-24 更新30

Supplementary Material for: Serum angiopoietin-2 levels predict the development of hepatocellular carcinoma following hepatitis C virus eradication using direct-acting antiviral agents

肝细胞癌预测

丙型肝炎治疗

Introduction: Our previous studies showed that serum angiopoietin-2 (Ang-2) and C-X-C motif chemokine ligand 10 (CXCL10) levels predicted improvement in liver fibrosis following sustained virological

DataCite Commons2024-07-25 更新80

Reasons for discontinuation of telaprevir and incidence of the most common AEs and Grade 3–4 AEs during the telaprevir phase in the intent-to-treat population.

药物不良反应监测

丙型肝炎治疗

* Includes six F0–F2 patients.† Listed are drug-related AEs that occurred in at least 5% of the overall population during the telaprevir phase.‡ Included in this category are all related events that w

Figshare2015-12-03 更新40

Table S1 - A Descriptive Model of Patient Readiness, Motivators, and Hepatitis C Treatment Uptake among Australian Prisoners

资源简介：

相关数据集